Convalescent (Immune) Plasma Followed by Intravenous Immunoglobulin Infusion in an Adolescent with Severe COVID-19

Year 2021, Volume: 23 Issue: 2, 221 - 224, 30.08.2021

Öner Özdemir , Bahri Elmas , Mehmet Cemal Dönmez , Hüseyin Sütlüoğlu

https://doi.org/10.18678/dtfd.938269

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has drawn attention over old immunotherapeutic agents such as convalescent (immune) plasma (CIP). Here, an adolescent with severe COVID-19 case requiring CIP and intravenous immunoglobulin (IVIG) treatments is described. A 17-year-old male patient was brought to the emergency room with complaints of fever, fatigue, and severe cough. Two doses of CIP were infused to the patient because of the increase in persisting fever, dyspnea, and acute phase reactant levels after the third day of routine protocol treatment. IVIG therapy was begun for 2 days at a dose of 1 g/kg/day due to resurgence in acute phase reactants and progressing radiological findings following CIP transfusion. Our patient avoided mechanical ventilation and showed immediate clinical and radiological improvement with CIP transfusion followed by IVIG therapy. Timely initiation of CIP treatment followed by IVIG prevented the disease from worsening and helped to reduce the requirement for mechanical ventilation.

Keywords

COVID-19, Convalescent (immune) plasma, intravenous immunoglobulin

Şiddetli COVID-19’lu Ergende Konvalesan (İmmün) Plazmayı İzleyen İntravenöz İmmünoglobülin İnfüzyonu

Abstract

Koronavirüs hastalığı 2019 (coronavirus disease 2019, COVID-19) pandemisi konvalesan (immün) plazma (CIP) gibi eski immünoterapötik ajanların üzerine dikkati çekmiştir. Burada, CIP ve intravenöz immünoglobulin (IVIG) tedavisi gerektiren şiddetli COVID-19 hastalığı olan bir adolesan olgu sunulmaktadır. 17 yaşında erkek hasta ateş, yorgunluk ve şiddetli öksürük yakınmalarıyla acil servise getirildi. Hastaya rutin protokol tedavisinin üçüncü gününden sonra devam eden ateş, nefes darlığı ve akut faz reaktan düzeylerindeki artış nedeniyle iki doz CIP infüzyonu uygulandı. CIP transfüzyonu sonrası akut faz reaktanlarında yeniden artış ve ilerleyen radyolojik bulgular nedeniyle 2 gün süreyle 1 g/kg/gün dozunda IVIG tedavisine başlandı. Hastamız CIP transfüzyonunu takiben IVIG tedavisiyle hemen klinik ve radyolojik iyileşme gösterdi ve mekanik vantilatör uygulamasından kurtuldu. CIP tedavisinin zamanında başlatılması ve ardından verilen IVIG, hastalığın kötüleşmesini önlemiş ve mekanik ventilasyon ihtiyacının azaltılmasına yardımcı olmuştur.

Keywords

COVID-19, intravenöz immunoglobulin, Konvalesan (immün) plazma

References

• Özdemir Ö. Coronavirus disease 2019 (COVID-19): Diagnosis and management. Erciyes Med J. 2020;42(3):242-7.
• Özdemir Ö, Melek Arsoy HE. Convalescent (immune) plasma therapy with all aspects: Yesterday, today and COVID-19. Erciyes Med J. 2020;42(3):252-9.
• Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-6.
• Melek Arsoy HE, Özdemir Ö. Current therapeutic interventions for COVID-19. Bezmialem Science. 2020;8(Suppl 3):105-16.
• Zhang J, Yang Y, Yang N, Ma Y, Zhou Q, Li W, et al. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review. Ann Transl Med. 2020;8(10):625.
• Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. Life Sci. 2020;258:118185.
• AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455.
• Bakhtawar N, Usman M, Khan MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: A systematic review of current literature. Cureus. 2020;12(8):e9535.
• Chai KL, Valk SJ, Piechotta V, Kimber C, Monsef I, Doree C, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;10:CD013600.
• fda.gov [Internet]. Food and Drug Administration. Investigational COVID-19 convalescent plasma -emergency INDs. [Cited: 2021 May 11]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds.
• Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12(8):571-6.
• Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunology. 2020;9(10):e1192.
• Abdolahi N, Kaheh E, Golsha R, Khodabakhshi B, Norouzi A, Khandashpoor M, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):549.
• Şeker E, Özdemir Ö, Pala A. Intravenous immunoglobulin therapy in COVID-19 disease. Sakarya Med J. 2021;11(2):470-2.
• Engin M, Özdemir Ö. Potential immunological treatments in COVID-19 patients. Duzce Med J. 2021;23(1):1-9.
• Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents. 2020;56(2):105974.